Distinguished in GTP Cyclohydrolase 1 Deficiency

Thomas Opladen

Heidelberg, BW, DE 
Distinguished in GTP Cyclohydrolase 1 Deficiency
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Thomas Opladen practices in Heidelberg, Germany. Mr. Opladen is rated as a Distinguished expert by MediFind in the treatment of GTP Cyclohydrolase 1 Deficiency. His top areas of expertise are Succinic Semialdehyde Dehydrogenase Deficiency, GTP Cyclohydrolase 1 Deficiency, Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, and Dopa-Responsive Dystonia.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of GTP Cyclohydrolase 1 Deficiency.

Gender
Male

Locations

Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Natural History Study of Patients with Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Natural History Study of Patients with Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Device, Procedure
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Completed
Publish Date: January 10, 2024
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
Enrollment Status: Terminated
Publish Date: January 25, 2022
Intervention Type: Drug
Study Drug: KB195
Study Phase: Phase 2
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
View 3 Less Clinical Trials

92 Total Publications

A CRISPR/Cas9 knockout model for AADC deficiency reveals structural loop3 instability as a key driver of catalytic failure.
A CRISPR/Cas9 knockout model for AADC deficiency reveals structural loop3 instability as a key driver of catalytic failure.
Journal: The FEBS journal
Published: June 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Opladen's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile